Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Shares of Bristol Myers Squibb Co. BMY shed 3.84% to $57.42 Thursday, on what proved to be an all-around mixed trading ...

The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers.

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...